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ABSTRACT 
 
Assessment of the Quality of Acute Flaccid Paralysis Surveillance Data in the World 
Health Organization, African Region 
Keith Shaba 
MPH, Mini-thesis, School of Public Health, University of the Western Cape 
 
Background: Poliomyelitis (polio) is an infectious disease of high public health 
importance. In 1988, the World Health Organization (WHO) set the goal of polio 
eradication worldwide through the Global Polio Eradication Initiative (GPEI). A three-
year period of zero indigenous wild poliovirus in all countries, in the presence of high-
quality acute flaccid paralysis (AFP) surveillance, is the basis of an independent 
commission’s determination of when  a WHO region or a country can be certified  as 
polio free. AFP surveillance being one of the critical elements in polio eradication 
campaign, aims to report and investigate all cases of acute flaccid paralysis occurring in 
children aged less than 15 years using clinical, epidemiological and laboratory methods. 
The information collected is cleaned and entered, into a database and maintained in EPI 
Info format at the WHO country office of each of the 46 countries, the three sub regional 
offices or Inter country Support Teams (IST) offices and the WHO African Regional 
Office. In addition, data from sixteen polio laboratories in various African countries 
maintain records of the laboratory findings and results of confirmed polio cases. 
   
The quality of data generated through AFP surveillance and maintained in the African 
regional data base has not been critically and systematically reviewed and documented. 
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This study therefore was designed to gather information and document the quality of AFP 
data base, a key component of the global polio eradication effort. 
 
Study Design and Sample Size: A cross-sectional descriptive study involving the 
retrospective review of clinical and laboratory databases of AFP surveillance over a five-
year period (2004 - 2008) was designed.  In this study, databases of CIFs containing 
clinical and laboratory data from AFP cases reported from all 46 countries of the WHO 
African Region comprising of 57,619 clinical and 59,843  laboratory records were 
critically reviewed.  
 
Data Collection and Analysis: Databases of reported CIF covering the period 2004 - 
2008 maintained in the Immunization and Vaccine Development (IVD) programme at the 
WHO Regional Office for Africa were accessed and checked for completeness and 
accuracy.  Data was analyzed using EPI Info version 3.3.2. For the purpose of this study, 
an error framework was developed with 4 major codes A, B, C, D and 11 sub-codes 
reflecting different elements of AFP surveillance. The proportions of missing data and 
incorrect entries were calculated for clinical and laboratory databases and displayed using 
tables and graphs. Comparisons were made in the numbers of errors between various 
countries and sub-regions and proportions in the tables generated were used to assess the 
association between the level of accuracy and completeness of data.  
 
Results: The study identified errors against all of 11 error codes in both the clinical and 
laboratory databases. Comparisons of data quality indicators between the clinical and 
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laboratory databases for the above period revealed that there are more errors in the 
clinical database than in the laboratory database.   
 
Conclusions: 
 
There are more errors in the clinical database than in the laboratory database. The analysis by 
major error groups in clinical database showed that the proportion of records with errors in 
groups A and B are not high (0.1-1.4%) compared with the other two groups (C and D). In group 
C, the dominant error group was C2 related to optimal time of specimen collection contributing 
13.3% of all errors in 2005, reduced to 8.6% in 2008. The errors identified have implications for 
the Global Polio Eradication Initiative with some of them being critical for the documentation 
and processes required for the certification of the African Region as polio free. 
 
Recommendations: Careful and frequent review of data and identification of errors and 
swift correction of these errors together with training and motivation of staff involved in 
data entry, collation, analysis and reporting as well as regular meetings to harmonize data 
should be pursued by all the countries.  
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CHAPTER ONE 
 
INTRODUCTION 
 
 
 
1.1 Background 
Overview of Polio Eradication initiative 
 
Poliomyelitis is an important vaccine-preventable infectious disease which affects mostly 
children and causes permanent paralysis in those who survive, resulting in a major economic 
burden to the families and individuals. In 2009 there were 1,606 cases of wild poliovirus (WPV) 
infections worldwide, 388 of which occurred in Nigeria. In addition outbreaks of polio affected 
19 previously polio-free African countries (Centers for Disease Control and Prevention 2010). 
The disease is thus an important public health problem and a major priority for eradication 
globally by the World Health Organization (WHO). The strategies for the eradication of 
poliomyelitis are: ensuring high routine immunization coverage (greater than 80%) with at least 
3 doses of oral poliovirus vaccine (OPV), supplementary immunization conducted as national 
poliomyelitis immunization days (NIDs), implementation of surveillance to identify any cases of 
Acute Flaccid Paralysis (AFP) for detecting new cases of the disease and mop-up vaccination 
campaigns once poliomyelitis is reduced to focal (WHO, 2000). The strategies for polio 
eradication thus depend largely on the availability of high quality AFP surveillance and 
immunization coverage data.  
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Importance of Surveillance Information 
The AFP surveillance data is used to determine which areas have transmission of the virus which 
causes poliomyelitis and together with the final laboratory results of virus isolation, 
identification and characterization allows the determination type of the polio vaccines (oral polio 
types 1, 2, 3, bivalent or trivalent vaccine) to use in response to stopping the spread of the virus 
in the population. In addition, by identifying the virus responsible for an AFP case, the origin of 
the virus can also be determined, in relation to viruses isolated from other regions or parts of a 
country or region, enabling response to be monitored in such areas as well. By serving as a 
measure of the success of the polio eradication programme, AFP data is also used for resource 
mobilisation in support of the Polio Eradication Initiative (PEI). For example, the GAVI Alliance 
has based its funding of immunization activities in developing countries on accurate, timely and 
easily verifiable immunization data, including AFP surveillance data (Lim Stein, Charrow and 
Murray, 2008). In some cases absence or inaccurate immunization data has led to the suspension 
of GAVI Alliance funding which in turn has adversely affected the PEI. Thus as routine 
immunization coverage improves the number of cases of disease decreases and surveillance is 
required to identify any cases occurring in those not immunized and to target them with 
supplementary immunization so as to eradicate or eliminate or control the disease eventually. 
This is critical for polio which has been targeted for eradication requiring that transmission is 
completely stopped.  
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AFP Surveillance  
Acute Flaccid Paralysis surveillance is a systemic monitoring for the presence of paralysis with a 
sudden onset, which could indicate poliomyelitis. The identification of cases of AFP requires 
laboratory investigation of stool specimens for presence of the polio virus.  The information 
generated is used for the GPEI. There are three main ways of conducting AFP surveillance 
(WHO, 2008): 
i) Active surveillance: is defined as regular visits by surveillance officers to health care 
facilities (clinics, hospitals, rehabilitation centres and traditional healers’ premises) to 
search for and investigate unreported cases of acute flaccid paralysis through a review 
of health records.   
ii) Passive Surveillance: this involves health facilities sending a report of AFP cases 
identified in the facility during the reporting period. 
iii)  Surveillance by community focal points: community focal persons (traditional 
healers, birth attendants, chiefs) who are likely to know about the occurrence of AFP 
case in the community are orientated on AFP symptoms so that they can report these 
cases to surveillance officers or health centres.   
 
Case Investigation Form 
All the information about each AFP case is carefully collected using a case investigation form 
(CIF) - Annexure 1. The CIF is used to record case information which comprises of patient 
information, demography, clinical and laboratory information, and follow up information.  The 
CIF is entered into two separate databases, one for the clinical data and the other the laboratory 
data.  The clinical database contains all information obtained after a clinical examination of the 
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AFP case by a health worker, while the laboratory database contains all the results of laboratory 
investigations of the stool specimen collected from the AFP case.  These databases form the AFP 
Surveillance system. 
 
Clinical and Laboratory Database  
An AFP clinical database is a collection of surveillance information derived from a case 
investigation form filled in at field level for acute flaccid paralysis. A laboratory database is a 
collection of information related to laboratory diagnosis and confirmation of the AFP. 
For the AFP surveillance system to be effectively implemented there is need for harmonisation 
of the two datasets or databases, in order to ensure that all information from the CIF is accurately 
entered in both datasets (WHO, Surveillance Guidelines, 2005).  
 
The process of AFP surveillance: The clinical databases are generated at the country level, and 
transmitted to their respective Inter-country Support offices (ISTs). The ISTs merge and clean 
the databases before onward transmission to the WHO Regional office (AFRO) based in 
Brazzaville. On the other hand, the laboratory databases originating from country level with 
clinical information filled and the laboratory section updated in the laboratory, are sent directly 
from the laboratories to the WHO Regional office where merging and cleaning are done.  
 
The people responsible for the cleaning and merging of the two databases are the surveillance 
officers, epidemiologists and data managers.  The person that is overall in charge of the AFP 
Surveillance is the WHO Regional Epidemiologist.  
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 Figure 1 Diagram illustrating the steps followed during AFP surveillance with 
accompanying stipulated timelines 
 
 
 
 
 
 
 
 
 
 
 
Exam should read “clinical examination”; lab should read “laboratory”; ITD should read “intra-typic differentiation”  
Source: WHO, Surveillance Guidelines, 2005. 
 
 
The processes involved in AFP surveillance as well as the timelines are illustrated in figure 1. 
The process begins by identification of a suspected case of AFP defined as a child under 15 years 
of age with acute (sudden onset) flaccid paralysis (weakness of the limb, arm, leg or both) or any 
person of any age when paralytic illness or polio is suspected by a clinician (Marx Glass and 
Sutter, 2000). 
 
Once the suspected case has been reported, a surveillance officer visits the suspected case to 
confirm that it is a true case of AFP. This health worker interviews the parents or guardians of 
Briefing Session of TFI Members October 2009 16 |
Processes of 
AFP surveillance
Virus isolation 
results reported
Isolates sent to 
regional lab for 
ITD
Onset of paralysis
Detection & 
notification 
Case investigation & 
specimen collection
Follow-up 
exam < 90 days of onset
Specimens 
arrive at 
national 
lab
< 7 days of 
onset
< 14 days of 
onset
> 60 days of 
onset
< 14 
days
< 3 days 
of being  
sent
Classification of 
case 
< 7 
days
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the case and conducts a clinical examination of the case before completing the case investigation 
form (CIF) and obtaining two stool specimens. The stool specimens collected are sent with a 
copy of the CIF to the designated laboratory for virological testing.   The information generated 
from the laboratory is sent back to the surveillance officer who then notifies the health centre on 
whether the case is confirmed as polio or not. All the processes have specified timelines within 
which they should be carried out as shown in the figure and which also serve as the basis of the 
indicators for monitoring the programme. 
 
When the case is confirmed as poliomyelitis the clinical information on the CIF is entered into 
the clinical database while laboratory information is captured in the laboratory database. Errors 
can occur at different levels such as when the CIF is being filled and when information is being 
entered in the clinical and laboratory databases. In addition, the entry of laboratory results at 
program level could also be an avenue for introducing errors. Delays can also occur at any of the 
stages, affecting the timeliness of reporting. 
  
Once the clinical and laboratory data are received at the IST and WHO regional offices, feedback 
is provided to the source of information in the form of a line listing highlighting all areas of 
concern. Where data gaps have been identified, possible solutions are suggested to correct errors 
and these are monitored to ensure that they have been corrected in the subsequent databases 
received. Before feedback is provided, the data quality checks would have been performed 
beginning with the CIF and subsequently the data that has been merged. 
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For this particular study, a standard template categorizing the types of errors in the two inter 
related databases, was developed in order to highlight the differences in the two sources of data. 
The categories chosen focused mainly on the five core variables that are used to calculate AFP 
surveillance indicators and monitor program performance (refer to annex) 
 
1.2 Problem Statement 
It has been found that the capture of CIF data for AFP surveillance has often resulted in 
numerous errors. The consequences of errors in the database and delays in rectifying them are 
that cases of poliomyelitis are overlooked or responses in the form of supplementary 
immunization or mop-up campaigns could be delayed, leading to the spread of the disease and 
delays in eradication efforts. Despite remedial actions such as regular follow up, monthly data 
harmonization meetings, to rectify errors arising from data entry as well the publication of 
feedback bulletins focussing on data discrepancies, the quality of AFP data has not significantly  
improved and remains a major challenge to the polio eradication programme in Africa (WHO, 
2005). Significantly, no systematic identification, quantification and categorization of the types 
of errors in the AFP surveillance data have been carried out in recent years. 
 
1.3 The Purpose of the Study 
The purpose of this study was to identify the types and to quantify the extent of errors in reported 
clinical and laboratory AFP datasets. Also to make recommendations aimed at improving data 
quality for AFP surveillance in the WHO Africa Region and to contribute to the subsequent 
eradication of polio from the continent.  
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1.4 Study Objectives 
 
1.4.1 Aim 
To assess the quality of clinical and laboratory data for AFP surveillance in the WHO Africa 
Region.   
 
1.4.2 Specific Objectives 
1. To identify the types of errors in the variables entered in the clinical and laboratory 
databases for AFP surveillance.   
2. To quantify the types of errors identified in the databases for various countries in the 
WHO African Region. 
3. To compare the errors, completeness and timeliness of reports in the clinical and 
laboratory databases for different countries and sub-regions. 
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CHAPTER TWO 
 
LITERATURE REVIEW 
 
 
2.1 Poliomyelitis as a Disease 
Polio is an enteric virus and expresses three important antigens (type 1, 2 and 3) associated with 
paralysis. These antigens are used to classify the three serotypes and are also the targets for 
vaccine development. Poliomyelitis also referred to as “polio” is a highly contagious, acute viral 
disease (Murray, Lopez and Mathers 2004). The virus is transmitted from person to person 
through the feaco-oral route with occasional transmission via milk, sewage and drinking of 
contaminated water (Pavlov et al. 2005). 
 
Though polio mainly affects children below 3 years old, it can also affect older children and 
adults. The disease progression was not clearly understood until 1870 that the lesions associated 
with poliomyelitis in the spinal cord were first described (Sutter, Kew and Cochi, 1988).  More 
recent research on poliomyelitis as a disease has focused on transmission, morbidity, and the 
disease burden. One in every 200 affected children becomes paralyzed, followed by permanent 
disability (Bernier, 1984, WHO, 2005), resulting in huge economic burden for the family and the 
country. The high mortality rate and the disabilities attributable to polio infection have increased 
the economic burden especially at the household and community levels (Thompson et al. 2008) 
About 5%- 10% of affected children with paralytic poliomyelitis have a fatal outcome (Kenji 
Shibuye, Murray, 1984). 
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For an estimated global birth cohort of 125 million for 2004, an estimated 600,000 people 
developed permanent disability due to paralytic poliomyelitis and up to 60,000 of these died 
from the disease. An additional burden of the disease is the high cost of rehabilitation and 
physiotherapy for survivors.  More resources are needed to provide support especially to disabled 
children (Murray, Lopez and Mathers 2004; Biritwum et al. 2001).     
 
The World Health Organization (WHO) and partners are collaborating to eradicate poliomyelitis 
worldwide. To monitor progress, countries perform surveillance for acute flaccid paralysis. The 
WHO African Regional Office (WHO-AFRO) and the U.S Centers for Disease Control and 
Prevention (CDC) are also involved in strengthening communicable  disease surveillance and 
response in Africa (http://www.biomedcentral.com/1471-2458/2/27/, Accessed on 15/05/2010).  
 
2.2 Clinical Manifestation of Poliomyelitis  
Infection with poliomyelitis is most often recognized by the acute onset of flaccid paralysis. 
Poliovirus infection occurs in the gastrointestinal tract and spreads mainly to the lymph nodes 
and central nervous system. Flaccid paralysis occurs in less than 1% of poliovirus infections; 
over 90% of infections are either unapparent or result in a non-specific fever (WHO, 2005).   
 
The paralysis of poliomyelitis is usually asymmetrical with fever present at onset. The maximum 
extent of paralysis is reached in a short period of time, usually 3-4 days. The legs are more 
affected than the arms. Paralysis of muscles supporting breathing can be life-threatening. Some 
improvement in paralysis may occur during convalescence but paralysis persisting after 60 days 
is likely to be permanent. 
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In paralytic polio, about 50% of patients recover with no residual paralysis, with about 25% left 
with mild disabilities, and the remaining 25% have severe permanent disabilities such as 
impaired hearing, speech, hydrocephalus and kyphosis (Lund et al. 2007; Lund and Lexel 2008; 
Lund and Nygard 2004).  
 
2.3 Prevention and Control of Poliomyelitis 
There is no treatment for poliomyelitis. Vaccination is the only cost effective method for the 
prevention and control of poliomyelitis (WHO Fact sheets, 2009). Equally important is the 
monitoring of protective immunity and maintaining surveillance to sustain the present polio-free 
situation (Nokleby et al. 2010). Subsequently several landmarks have been achieved including 
the development of effective vaccines and introduction of the goal of global eradication of the 
disease by 2005 (Murray, Lopez and Mathers 2004; WHO, 2000). Through vaccination most of 
the developed countries have eradicated poliomyelitis. The Global Poliomyelitis Eradication 
Initiative and the GAVI Alliance are providing funding for the eradication of this disease in 
African countries and within the Expanded Program on Immunization (EPI), which targets 
children under-five years old. The programme provides free of charge, the oral poliomyelitis 
vaccine (OPV) during routine immunization activities at health facilities and during national 
immunization days (NIDs) through fixed, door to door and outreach strategies.  
  
There are two main types of polio vaccines developed by American scientists Salk and Sabin 
available: the more expensive inactivated polio vaccine (IPV), which is administered by injection 
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and the much cheaper, live oral polio vaccine (OPV) given orally (Murray, Lopez and Mathers 
2004).  
 
In 1963, trivalent live oral polio vaccine (Sabin), incorporating the three types of poliomyelitis 
viruses (1, 2, 3) replaced IPV as the recommended polio vaccine.  Most countries have 
commonly used oral polio vaccine for preventing poliomyelitis because of the ease of 
administration and enhanced mucosal immunity, low cost and the ability to boost population 
immunity and subsequently interrupt transmission of the virus. Secondary spread of this live 
Sabin-derived vaccine virus can occur from vaccinated to unvaccinated close contacts conferring 
herd population immunity (WHO Weekly Epidemiologic Record, 2003). 
 
The development and licensure of monovalent types 1 and 3 live oral polio vaccines (mOPV1 
and mOPV3) have provided the Polio Eradication Initiative with new and additional vaccines 
against disease caused by the specific poliovirus types 1 and 3 that are prevalent in Africa. For 
example, the use of mOPV1 in Nigeria in 2006 was partly responsible for the remarkable 
reduction in the wild poliovirus type 1 infections experienced in 2007 (WHO, 2008). 
  
2.4 Global Polio Eradication Initiative 
The Global Polio Eradication Initiative was launched at the 41
st
 World Health Assembly in 1988, 
with the aim of eradicating poliomyelitis by 2005 (WER No. 36, 2009). The initiative involves 
several partners such as Rotary International, USAID, CDC, JICA, UNICEF and many others. 
Due to persistence of wild poliovirus in Asia and African countries, the 2005 target was not 
achieved. Supported by the World Health Organization and the Center for Disease Control and 
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Prevention, the STOP (Stop Transmission Of Polio) initiative was later created with the aim to 
eradicate Polio from the globe by the Year 2010 (Nsubuga et al. 2002). 
 
The Global Polio Eradication Initiative has made remarkable progress showing the incidence of 
polio has decreased from an estimated 350,000 cases annually to 1,655 reported over the period 
1988 to 2008 and 1606 WPV cases in 2009 (WHO, 2008, WER No.12, 2009, WER No.18, 
2010). Global vaccination efforts have contributed to this progress. By 2005, indigenous 
transmission of wild poliovirus (WPV) types 1 and 3 (WPV1 and WPV3) had been eliminated 
from all but four countries (Afghanistan, India, Nigeria, and Pakistan). No cases of WPV type 2 
have been reported since 1999. Despite the progress, Nigeria and India still remain polio-
endemic countries and some sporadic WPV cases have been notified in some other parts of 
Africa and Asia. Early this year new cases of paralytic polio due to WPV have been reported in 
Tajikistan raising fears of the re-emergence of polio in parts of Europe several decades after its 
eradication from the region (WHO 2010).  
 
2.5 Polio Eradication in the African Region 
The number of polio-endemic countries in the African Region has declined from 11 in 2000 to 
just one, Nigeria in 2008, with an 89% decrease in the number of reported cases of WPV within 
the same period (Polio News, 2009). This success has been attributed to high immunization 
coverage during mass vaccination campaigns, good AFP surveillance, appropriate logistics and 
the availability of funds. Currently there are 15 other countries in Africa with wild poliovirus, 
largely due to importations of the virus from Nigeria and so constituting a major setback to the 
eradication initiative on the continent (WER No.14, 2009, WER No16, 2009). The last few cases 
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were reported from Kenya and Uganda signaling that the threat of polio is still great for the 
African continent. Currently WPV is transmitted in the Horn of African region (Ethiopia, Kenya 
and Uganda) and in West Africa (Togo, Nigeria, Cote d’Ivoire, Burkina Faso, Mali and Niger) 
(see figure 2 in annex). 
 
2.6 Surveillance for AFP and Laboratory Identification of Polioviruses from Stool Samples 
 
Remarkable progress towards polio eradication has been noted globally (WER, 2009). 
Surveillance for cases of AFP and examination of stool specimens from AFP cases for the 
detection of poliovirus provides important data to target supplemental immunization activities 
(WER 1998). This is critical for the planning of immunization campaigns using the appropriate 
OPV type to ensure that the virus is eliminated in line with the GPEI’s requirement for the 
eventual certification of polio-free status of a country or region (Kew et al. 2005). 
  
The presence of AFP as a proxy indicator of infection with poliovirus with a high sensitivity 
level has strengthened the surveillance system by capturing all cases of poliomyelitis including 
atypical presentations and identifying cases of poliomyelitis due to spread of the vaccine strains.  
The number of AFP cases notified per 100 000 children less than 15 years within a given time 
depict the quality of surveillance activities, even when there are no cases of poliomyelitis (WHO, 
2008). A global network of accredited laboratories has been established for the processing of all 
stool samples in support of this surveillance. 
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Standards have been set for the certification of polio-free status. Among others the certification 
standards require that countries continue to demonstrate high levels of surveillance indicators 
(WHO, WER No.18, 2004).  
 
2.7 Challenges in Monitoring AFP Surveillance  
Surveillance for poliovirus remains the cornerstone of monitoring the progress of the 
poliomyelitis eradication initiative (PEI). The process includes notification and careful 
investigation of cases of acute flaccid paralysis (AFP), collection of stool specimens from the 
suspected patient in a timely manner, and virological examination of the specimens in a WHO 
accredited laboratory for the confirmation of polio. Successful high quality AFP surveillance 
requires adherence to the approved Standard Operating Procedures and smooth interplay of 
several different groups involved in obtaining surveillance data (Hovi, 2006). 
 
The performance of AFP surveillance is based on a number of indicators as shown in Table 1 
(WHO, 2003). The accuracy of each of these indicators is determined by the timeliness and 
completeness of reporting at each level of collection as well as proper handling of stool 
specimens, including conditions of their shipment, and the capacity of the laboratory to perform 
the required analysis. 
 
There are several factors which affect the quality of AFP surveillance and these include data 
quality, availability of resources, and training of health personnel in surveillance including 
laboratory staff and community participation in surveillance at grassroots level. The present 
study will focus on the quality of data as a major affecting surveillance for AFP. 
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2.8 General Overview on Data Quality 
In the context of disease control programs, ensuring high quality of data requires going through 
the data periodically, updating, standardizing and correcting duplicate records to create a single 
record of the data, even if it is stored in multiple disparate systems (WHO, 2001). Data quality 
encompasses ensuring the reliability and authenticity of data for use in effective decision-making 
for disease control and prevention. 
 
There are many reasons as well as several ways in which the quality of data may be 
compromised. These include introduction of errors during data entry, errors in analysis and 
reporting due to differences in data collection and reporting formats, inadequate performance by 
personnel and high staff workload (Harris et al. 2003; de Gourville et al. 2006; Danovaro et al. 
2007). In a comprehensive study in Mozambique, the quality of quarterly aggregate summary 
data compiled and reported for antiretroviral treatment facilities was compared with Ministry of 
Health data for the same period. The study revealed that many health facilities reported 
inaccurate data and several facility-level characteristics (Makombe et al. 2008), as already 
enumerated were associated with data quality. Some of the reasons stated may be responsible for 
the poor quality of immunization data, including AFP Surveillance data at national, country, the 
inter-country support, laboratories and the WHO Regional Office. However this requires 
confirmation through a careful and systematic review. 
 
 The improvement of the quality of data will require identification of the sources and levels of 
errors and the competence of all personnel involved in the handling and transmission of AFP 
data and corrective measures put in place (Birmingham et al. 1997). 
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2.9 Vertical versus Integrated Surveillance Systems  
Typically each vertical health program runs its own system with little regard to how information 
is integrated or is beneficial to the overall system. Centralization of statistical systems is 
advantageous where technical resources and expertise are in short supply (Macfarlane, 2005). 
However, most developing countries operate fragmented and disjointed disease surveillance 
systems resulting in collection of unreliable and unrepresentative data. The insufficient number 
of staff and their low capacity has negatively impacted on the timeliness and completeness of 
AFP surveillance data in most developing countries especially in Africa.  The current AFP data 
collection system is regarded as vertical involving collection of data from the periphery and 
transfer progressively to the central level on a weekly basis.  
 
2.10 Country Experiences and Research in Quality of Disease Surveillance 
In 1985, the Pan American Health Organization (PAHO) adopted an initiative to eradicate 
poliomyelitis from the Western Hemisphere. They conducted a study to screen cases of AFP for 
poliomyelitis eradication as a way of improving specificity.  In a cross sectional retrospective 
study conducted in the countries of Latin America, all AFP affecting children less than 15 years 
old were reported and investigated. Data quality was a critical point at the stage of polio 
eradication indicating the absence of wild poliovirus circulation in the WHO American Region 
(Andrus et al. 1992). The extent to which AFP data differs for different countries in Africa is not 
very clear because few studies have been conducted. 
 
The inaccuracy of data has been reported in other studies in Africa. For example in a study 
carried out in Malawi to assess the quality of data, the accuracy of data was classified as 
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inadequate if there was 5% or more missing variables. This study revealed that while most sites 
offering health services had complete case registration and outcome data, many sites did not 
report accurate data for several critical data fields such as reasons for starting the treatment, 
outcome of treatment, and the treatment regimen. The national summary using the site reports 
resulted in 12% less in total number of persons on first-line treatment (Makombe et al. 2008).  
 
In another study conducted in Mozambique (Mavimbe, Braa and Bjune 2005), the quality of the 
measles reporting system was studied. There were significant differences in data between facility 
reports and tally cards. Similar differences were encountered in data from health facilities when 
compared to district health data. Routine practice during supervision visits failed to focus on data 
inconsistency between the tally sheets and the facility reports.   
 
Assessing the routine surveillance data for measles Jagrati and others showed a significant 
under-notification of measles cases resulting in inappropriate evidence-based decisions and not 
allowing in-depth analysis to monitor measles epidemiology in the country (Jagrati et al., 2006). 
In the Americas, a study assessing the immunization coverage data and procedures used to 
calculate coverage figures using DPT3 showed clear incompleteness and inconsistencies in data 
analysis (Danovaro et al, 2007). The studies reviewed are some of the examples of inaccuracies 
in data from health programmes in different parts of the world. 
 
2.11 Assessment of Data Quality 
Disease surveillance is necessary to identify priority areas and plan strategies of operation. The 
surveillance system needs to be strengthened for the collection of data on EPI target diseases for 
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measuring the impact of immunization on reduction of morbidity, mortality, and disability (Basu 
1982). In general, there are several ways to assess the quality of data. These include periodic 
reviews of the data, prospective studies to evaluate the whole process from capture, entry, 
transfer, analysis and reporting as well as use of continuous monitoring tools. The GPEI has 
specific tools which have been made available to countries to enable them assess data quality, 
identify errors and their sources and to correct them in a timely fashion. These methods include 
the Data Quality Survey (DQS) (Woodard et al. 2007), monthly data harmonization meetings, 
publication of feedback bulletins with focus on quality and programmatic issues, and the use of 
cluster surveys (WHO, 2009). Despite the availability and use of these tools by countries in 
Africa the quality of immunization data in general and AFP surveillance data in particular still 
has inaccuracies, year after year. 
 
2.12 Challenges of Data Quality in the African Region 
Data quality is a major concern in public health programs especially the inaccuracies in 
immunization data.  The extent of inaccuracies in immunization data in the African Region 
compared to other regions has not been well established.  
 
Available reviews of routinely collected health records suggest that mechanisms to ensure data 
quality through supervision, harmonization of data and collection tools, and data quality 
assessments contribute to the quality, timeliness and accuracy of data and thus correcting these 
factors would improve data management practices (WHO Weekly Polio Updates, 2008)   
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The Global Alliance for Vaccine and Immunization (GAVI) has developed a standard tool for 
the quick assessment of the quality of data, the Data Quality Audit (DQA) (Ronveaux et al. 
2005). This audit involves the provision of a standard data checklist for countries to use in 
auditing their data but has never been used to formally study data quality in Africa (WHO, 
2005). A simulation has however revealed that the DQA lacks the precision it is supposed to 
have due to inadequate sample size (Woodard et al. 2007). Despite this the DQA is 
recommended as an innovative tool for the independent assessment of the quality of 
immunization monitoring systems, by identifying inconsistency in immunization data and 
providing a means of improvement of data quality (Ronveaux et al. 2005). 
 
 
There is clearly an urgent need to determine the quality of AFP surveillance data within the 
GPEI in the WHO African Region and to identify the factors which could compromise the 
quality of data and propose ways to improve data quality in the region. 
This study was designed to use available proven tools to retrospectively review the AFP 
surveillance data in the African region. 
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CHAPTER THREE 
  
METHODOLOGY 
 
 
3.1 Study Design 
This was a cross-sectional descriptive study involving the retrospective review of clinical and 
laboratory databases of AFP cases collected over a five-year period (2004 - 2008) by 46 Member 
States of the WHO African Region.  
 
3.2 Study Area and Population 
All the clinical and laboratory records including case investigation forms of AFP cases reported 
over a five-year period (2004 to 2008) from 46 countries involved in the GPEI program in the 
WHO Africa Region were used for the present study. These countries were grouped by WHO 
Regional Office for Africa (AFRO) for operational purposes into three sub-regions referred to as 
Inter-Country Support Teams (IST): West IST- with 17 countries, Central IST- with 11 countries 
and South East IST with 18 countries (Appendix 2).  
 
3.3 Sample Size 
A sample size was not estimated for this study as the entire sum of reported AFP cases from 
2004 to 2008 (five years), comprising 57,619 clinical and 59,843 laboratory records were 
reviewed. 
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3.4 Sampling Procedures 
No sampling procedures or techniques were required for the present study as it was based on the 
review and analysis of previously collected data. This required systematically going through the 
databases and identifying errors such as missing values, wrong entries and incomplete entries. A 
standard tool developed by the WHO (WHO, 2005) for the identification and logging of errors 
was used. 
 
3.5 Data Collection  
Database of reported CIF covering the five year period, 2004 to 2008 maintained in the 
Immunization and Vaccine Development (IVD) programme, at the WHO Regional Office for 
Africa was accessed and checked for completeness and accuracy. The databases by year of 
reporting are kept in EPI Info software on a shared drive at the IVD programme. Permission was 
sought from the IVD Programme Manager and all the administrative arrangements were made 
prior to the use of the data. No specific data collection techniques were required as previously 
collected data was used for the study.  
 
3.6 Data Analysis  
The different types of errors in the databases were identified and all tabulated. Comparisons of 
the total numbers and proportions of the different types of errors were compared for different 
variables such as sub-regions and countries, types of errors and trends over the past five years.  
 
Data was analyzed using EPI Info version 3.3.2 (CDC, 2006). A report was considered complete 
if it contained critical variables (EPID number, date of onset, dates of 1
st
 and 2
nd
 stools 
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collection, date specimen received in the laboratory, primary and ITD laboratory results) used 
calculate indicators while accuracy was determined by correct matching between surveillance 
and laboratory databases.  Proportions were compared using different tables produced (Figure 3) 
to determine the number of errors in each given category.   
 
3.7 Validity and Reliability 
Completeness and accuracy of data have been clearly defined to ensure that there is standard 
methodology of assessing the errors. A previously validated data quality assessment technique 
(WHO, 2005) was used to assess the quality of data while the surveillance guidelines protocol 
was used to assess the methodology of generating outputs. Selection bias has been eliminated as 
all records for the study period were reviewed. The reliability of assessment of errors was 
assessed by re-assessing a 1% sample of records for levels of error and completeness. Data was 
subjected to standard statistical analysis.  
 
3.8 Generalizability of Results 
The use of the entire population allows the results of the assessment of quality (accuracy, 
completeness and timeliness) to be generalizable to the situation in the 46 countries of the WHO 
Africa region for the study period. The outcome may also be applicable to other health related 
data collected by programmes in the African region since practices and policies for the various 
programmes of the Ministries of Health (MOHs) are similar and based on guidelines provided by 
WHO. The outcomes of the present study are however limited to the period covered by the data 
and cannot be applied to any other period (previous or later).   
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3.9 Limitations 
While the present study assessed the quality of data and the common factors which could have 
compromised data quality, the study faced a number of limitations characteristic of similar 
studies. It was impossible to adduce all accurate reasons for the errors which were identified 
since the study was retrospective. 
3.10 Ethical Statement 
Ethical approval of the proposed study was sought from the Faculty of Community and Health 
Sciences and the UWC Ethics Committee. Permission was also sought from the Programme 
Manage, Immunization and Vaccines Development Programme of the Division for the 
Prevention and Control of Communicable Diseases, Regional Office for Africa, World Health 
Organization.  Names and other information which could identify individuals were deleted to 
ensure the protection of the rights of individuals to privacy, which is consistent with guidelines 
of Ethical research involving human subjects (ICH Guidelines).  
3.11 Data Storage and Cleaning 
Data are stored electronically in EPI-Info format at WHO level and hard copies filed at country 
level. The data which was used in the present study had been cleaned during monthly data 
harmonization meetings, from feedback, and regular flagging of data quality issues in the 
modules used. Data cleaning programs components have been incorporated in all modules used 
for data capturing at country and WHO levels.  
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CHAPTER FOUR 
 
RESULTS 
 
 
 
The study consisted of the analysis of clinical and laboratory databases for 46 countries of the 
WHO African region, received at the WHO Regional office for the period 2004 – 2008. 
4.1 Number of AFP Cases Expected versus Reported in Clinical Database 
One of the key indicators of polio surveillance is the reported AFP rate. The standard indicator 
for the certification of a region as being free of poliomyelitis is pegged at 1 non-polio AFP case 
reported per 100,000 people below 15 years of age as an indication of a functional surveillance 
system (WHO Regional Office for Africa, 2005).   
 
Table 1 below shows the expected AFP cases by year versus number of AFP cases reported 
using the above criteria.  
 
Table 1: Expected AFP cases by year versus number of AFP cases reported in clinical 
database (1/100,000 population <15 yr.) 
 
Year  Expected AFP cases *  Reported AFP cases Reported AFP rate ** 
2004   2917      8560     2.9 
2005   3189    11341     3.2 
2006   2743    12067     3.8 
2007   2873    11355     3.7 
2008   2942    14296     4.5 
* = Expected number of AFP cases is computed by dividing countries’ population for under 15 years by 100,000. 
These are estimates. 
  
** = Reported AFP rate is calculated using actual reported AFP cases for given year divided by under 15 year olds 
population 
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The table above indicates that throughout the years under study, the reported AFP cases far 
exceed the expected level indicating that countries’ performance for this indicator is in general 
satisfactory.   
 
In order to capture wild poliovirus among reported AFP cases, WHO established a standard of 
two stool specimens per single reported AFP case to be taken within 14 days of onset of 
paralysis, 24-48 hours apart. Table 3 below represents compliance of the countries in the African 
Region with this requirement. 
 
 
Table 2: Total number of AFP cases reported versus number of stool specimens taken in 
the clinical database *) 
 
Year   Total # AFP   Stool samples taken    Specimen 
  Cases reported   ---------------------------------------------      not taken (%) 
     1 sample (%) 2 samples (%) 
2004    8560      69 (0.8)   8468 (99.1)    23 (0.3) 
2005  11341      82 (0.7) 11230 (99.0)    29 (0.3) 
2006  12067      14 (0.9) 11920 (98.8)    33 (0.3) 
2007  11355      78 (0.7) 11255 (99.1)    22 (0.2) 
2008  14296      87 (0.6) 14176 (99.2)    33 (0.2) 
Total  57619    430 (0.7) 57619 (99.1)  140 (0.2) 
*) Note: The clinical database is used to avoid duplication with the data in laboratory database. The clinical database 
is the initial step in AFP investigation leading to specimens being delivered to the laboratory.   
 
 
The data in Table 2 indicates high compliance of countries (99.1%) with the standard 
requirement of collecting two samples per each reported AFP case. The proportion of AFP cases 
without a sample or with only one sample taken is low ranging from 0.2 to 0.3% and 0.6 to 0.9% 
respectively during the study period. This is not negligible, because as proportions of the total 
number of AFP cases, 140 potential cases of poliomyelitis could be missed leading to spread of 
the virus, polio being a highly infectious viral disease. When an AFP case is missing stool 
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specimen, such a case (after being notified) is normally followed up within 60 days to verify 
whether or not the patient eventually develops residual paralysis. If found to have residual 
paralysis or lost during follow up, (misplaced, death, etc.), such a case is classified as “Polio 
compatible” otherwise, it is discarded. However within the 60 days there is a likelihood of the 
transmission of the virus if indeed the AFP case turns out to be polio. This becomes a serious 
setback to the PEI program.  
 
4.2 Status of clinical and laboratory databases  
Proportion of annual AFP cases reported by year is shown in Figure 1 which indicates an 
increase in the number of reported AFP cases in the clinical database although throughout years 
under study a slight decline was observed in 2007 while the number of AFP cases in the 
laboratory database continued steadily to increase.   
 
Figure 2: Reported AFP cases in clinical and laboratory databases, 2004-2008. 
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Figure 2 also provides data showing that the annual trend of reported AFP cases in the laboratory 
database was always more than in the clinical database with the exception of the year 2008. The 
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data shows a steady increase in the number of cases in both the clinical and laboratory databases 
from 2004 to 2008, except in 2007 when there were declines in numbers of cases for the two 
databases in 2007.  
 
4.3 Identification of Errors in the clinical and laboratory databases 
 
Data cleaning process using error identification program detailed in Appendix 2 revealed a total 
of 11 different types of errors distributed in 4 major groups (A, B, C, D) reflecting different 
elements of AFP surveillance: EPID number, date of onset, date on which stool sample was 
taken and the laboratory results as shown below in Table 3. This program was designed to 
identify gaps in data which can broadly be categorized as incomplete and wrongly formulated 
EPID numbers, missing information in key variables used for calculation of indicators of 
performance, illogical date entries leading to negative intervals and mismatches of information 
among related fields.  
 
Table 3: Different types of errors identified in the clinical and laboratory databases,  
2004-2008          
 
 
Error type CODEs 
Identified errors in the clinical and laboratory databases 
 
   A 
A1 Wrong formulation of EPID Number (dash is missing in EPID number to separate codes) 
A2 Incomplete EPID Number (year or case number has an “x” or blank space) 
A3 Year in EPID Number and in the date of ONSET do not match 
   
   B 
B1 Cases missing date of onset 
B2 Cases with year of onset not matching year of the database 
 
   C 
C1 Date of onset and date 1
st stool collected with negative interval  
C2 Cases where date of onset and stool collected is greater than 14 days  
C3 Cases where the interval between dates of 1
st and 2nd stool collected is negative or >48 hours 
 
   D 
D1 Cases with missing date specimen received in the laboratory 
D2 Cases with missing primary isolation results  
D3 Cases with missing intra-typic differentiation results  
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The analysis included a total of 17,857 error cases categorized in 4 major codes with their 
individual proportions shown in Figure 3.   
 
 
Figure 3 
Distribution of types of errors by 4  major codes (A, B, C, D)
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Frequency of identified errors was highest (64.1%) for error group “C” related to stool specimen 
collection dates followed by group “D” related to laboratory results, which was 31.0%. The other 
two groups A (EPID number discrepancies) and B (inaccuracies related to date of onset) 
constituted small proportions among the total number of errors (4.7% and 0.1%).  Description of 
errors per type of database is given in the following sections.  
 
4.4 Errors in the Clinical Database 
Analyses in this database were conducted on 57,619 records of AFP cases. Figure 4 represents 
the proportion of errors identified in this database among all AFP cases entered showing 20% 
level which by surveillance standards is considered to be high.  
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Figure 4 
AFP cases and total errors identified in clinical database
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80%
AFP cases with errors Reported AFP cases
 
 
Table 4 below details the numbers and proportion of errors against 11 specific error codes 
identified for the period under study. Proportions of errors were calculated using their number 
over total reported cases while for proportions of missed ITD results – error code D3, the 
denominator was the number of positive isolates based on information given by the laboratory. 
 
Table 4: Number of errors in the clinical database, African Region, 2004 - 2008  
Type of error  2004  2005  2006  2007  2007 
    n (%)  n (%)  n (%)  n (%)  n (%) 
A1            117 (1.4)          157 (1.4)              8 (0.1)              5 (0.0)              2 (0.0) 
A2                4 (0.0)             7 (0.1)              0 (0.0)              0 (0.0)              1 (0.0) 
A3                1 (0.0)             6 (0.1)              6 (0.0)              2 (0.0)              0 (0.0) 
B1                4 (0.0)             6 (0.1)              3 (0.0)              0 (0.0)              0 (0.0) 
B2                1 (0.0)             0 (0.0)              1 (0.0)              0 (0.0)              0 (0.0) 
C1                6 (0.1)           28 (0.2)              8 (0.1)              8 (0.1)              10 (0.1) 
C2          908 (10.6)     1505 (13.3)      1241 (10.3)          981 (8.6)              1276(8.9) 
C3                7 (0.1)             4 (0.0)              0 (0.0)            10 (0.1)               6 (0.0) 
D1          991 (12.0)         914 (8.1)          722 (6.0)          801 (7.1)            444(3.1)  
D2            119 (1.4)         154 (1.4)          222 (1.6)          215 (1.5)             20 (0.1) 
D3              98 (7.7)           81 (5.4)            37 (2.4)        296 (36.2)           48(34.0) 
 
Analysis of the table indicates high prevalence of D3 and D1 coded types of errors throughout 
the period under study ranging from 2.4% to 36.2% (cases missing date of specimen receipt in 
laboratory) and 3.1% - 12.0% (cases with missing ITD results) respectively. The next error 
category which had high incidence was group C2 (cases with inadequate interval between onset 
and date of stool specimen taken) with incidence rate of 8.6% - 13.3%. The results also show 
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errors against other codes: A1 code (wrongly formulated EPID number) - 0.1% - 1.4%; B1 
(cases with missing date of onset) - 0.1% - 0.2%, D2 (cases with missing primary isolation 
results) - 0.1% – 1.6%.  As for code B2 (mismatch of dates of onset and database), remarkably 
there were no errors identified over a five year period. Although errors in group A1 decreased 
after 2006, the analysis showed their higher values compared to other types of errors within 
group A.  
 
4.5 Desegregation of most Prevalent Errors in the Clinical Database by Country and by 
IST  
The following three tables (5-7) represent the number of cases with missing specimen receipt 
dates in the clinical database (error code: D1) by country in the sub-region for the five year 
period. 
Table 5: Distribution of cases with missing specimen receipt dates in the countries of the 
IST West (Error code D1) 
Country   2004        2005      2006        2007     2008  Total  
Burkina Faso    58           51           43             18         99  269  
Cote d’Ivoire      5             4             4           203           1       217 
Guinea      79           48             6             37          42  212   
Mali      61           79             7               3               0   150         
Senegal        0             0          145     2            0   147               
Níger      20           21            21            55            9  126 
Sierra Leone     33           27              0             11          19   90    
Liberia      15           50            10            10            0   85               
Nigeria        0             0              1              50          13   64 
Togo        3           36              9              0          12   62  
Mauritania       9           16              9             12            2   48    
Gambia        3           12              3               3            4   25   
Algeria      16             0              0              0           7   24    
Ghana        1             1              0            12            6   20   
Guinea-Bissau       4             0              0                3           2     9 
Cape Verde       1             0              3               1           1     6 
Benin        1             0              0               1           0     2 
Total IST West  309         347              261                     421                    217              1555  
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Burkina Faso, Cote d’Ivoire, Guinea had the highest number of cases 269 (17.2%), 217 (13.9%) 
and 212 (13.5%) respectively of the total number of errors (1555) in IST West. The first 5 
countries in the table contributed 64% of all errors in IST West. Benin, Cape Verde and Guinea-
Bissau had the least number of errors. The total number of D1 errors was fluctuating during the 
study period. Most of the errors- 421 (26.9%) were identified in 2007.  
 
Table 6: Distribution of cases with missing specimen receipt dates in the countries of the 
IST Central (Error code D1) 
 
Country    2004        2005 2006      2007     2008  Total  
--------------------------------------------------------------------------------------------------------------------------------- 
Chad      119          162      7        2           6      296  
Central African Republic    120           126      0        0           0    246 
Congo        35            53      3        2           0      93 
Republic Democratic of Congo       0  5    30       34           0      69 
Angola        11  0    15       32           1      59 
Rwanda               6  7    21         6           7      47  
Burundi                4  3    18         7           3      35  
Gabon          7              8      0         0           1      16 
Equatorial Guinea        6  4      0         2           0      12 
Sao Tome and Principe         0  0      2         0           1        3 
Total IST Central     308          368    96       85         19    876  
 
 
Of the total number of errors recorded, 33% (296) were from Chad representing the highest 
number of cases with missing specimen receipt date in the clinical database. Chad and Central 
African Republic together contributed about 62% of all errors in the sub-Region. Sao Tome and 
Principe had the least number of errors (3). There was a remarkable decrease in D1 code errors 
throughout the study period from 308 cases in 2004 to just 19 cases in 2008. 
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Table 7: Distribution of cases with missing specimen receipt dates in the countries of the 
IST South/East (Error code D1) 
Country    2004        2005 2006   2007        2008  Total  
Namibia                5           14   273       31            90   414  
Tanzania       18            57       24     135               5   244 
South Africa      193           14           2         5              2   216  
Zimbabwe       95           19           7       34            18   174  
Malawi             35           28       18       22            33   136 
Eritrea          2           49       10       16            32   109  
Mozambique         2             0           3       15            21     41  
Lesotho             3             3       15       12             0          33 
Kenya        16             5           2         3             2          28 
Zambia               0             1           5         7             3          16      
Botswana         0             4           0         5             0              9  
Madagascar         3             1           0         4             1              9 
Ethiopia                0             0           4         4             0              8 
Comoros         0             0           0         2             1              3  
Total IST South/East    372              195               363     295         208   1433       
 
 
 
In IST South/East, Namibia had very high rate of D1 errors - 28.8% (414). The first five 
countries in the table had more than 80% of all errors recorded by countries in this IST. The last 
5 countries in this IST had the lowest levels of D1 code errors ranging from 3 (Comoros) to 16 
(Zambia). 
 
As shown in Figure 5, there was in general a reduction in the prevalence of errors in the clinical 
database for all three ISTs from 2004 – 2008; reduction by 93.8% in IST Central, 29.8% -  IST 
West and 44.1% in IST South/East.  
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Figure 5: D1 code errors by sub-region (ISTs) and year for the countries of the WHO 
African region 
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A closer look at the number of errors in Figure 5 over the period of time shows that:  
IST West: The trend in number of errors showed a fluctuation of between 309 in 2004 and 347 
in 2005, followed by a drop to 261 in 2006. This was followed by a sharp rise the following year 
to 421 and then reaching 217 in 2008. The countries with relatively high numbers of errors in 
2004 were Guinea (79), Mali (61), Burkina Faso (58), Sierra Leone (33) and Niger (20). Nigeria, 
with the largest population and also the only endemic country of the region and with on-going 
polio virus transmission (CDC, 2011) over the period, significantly did not have any D1 code 
errors in 2004.  
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IST Central: There was an increase in errors from 308 in 2004 to 368 in 2005, followed by very 
significant and steady decline for the rest of the years to 96 and 85 (2006-07) and finally to 19 in 
2008.  
 
IST South East: There was a fluctuation similar to the data for IST West from 372, 363, and 
208 in 2004, 2006 and 2008 respectively. This was due to the large numbers of errors in two 
countries, Namibia with a very small population with 273 in 2006 and Tanzania with 135 errors 
in 2007. 
 
4.6 Errors in the Laboratory Database  
 
The laboratory database consisted of 59,843 records of AFP cases for the period 2004 - 2008. 
These records represent data compiled from the 16 national and 10 WHO Reference laboratories 
for ITD results.  
 
 
The number of errors in this database was 6,383 representing 11% of the total errors as shown in 
Figure 6. 
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Figure 6 
AFP cases and total errors identified in the laboratory database
11%
89%
AFP cases with errors Reported AFP cases
 
 
Errors per identified codes are presented in table 9 which shows frequency of various errors 
within major codes A, B, C, and D for the period under study. Compared with the clinical 
database, these proportions of errors in general are lower and in some error areas, such as B1, 
B2, and D1 no errors were recorded.  
 
Table 8: Number and Proportion (%) of Errors in the Laboratory Database, African 
Region, 2004 – 2008*) 
 
Type of error  2004    2005  2006  2007  2008  
   n(%)                  n(%)  n(%)     n(%)              n(%) 
AFP cases in       9761  11490  12152  12186  14254 
Positive samples  1346    1405    1399     775    1300  
 
A1               7 (0.1)   10 (0.1)               24 (0.2)   12 (0.1)  13 (0.1) 
A2             41 (0.4)  37 (0.3)             231 (1.9)                34 (0.3)  38 (0.3) 
A3               9 (0.1)    6 (0.1)               41 (0.3)                14 (0.1)  12 (0.1) 
B1                   0       0       0       0       0  
B2                   0      0       0       0       0  
C1             17 (0.2)  22 (0.2)                 22 (0.2)            17 (0.1)                 4 (0.0) 
C2           899 (9.2)           1381(12.0)              1103(9.0)          933 (7.7)              1078 (7.6) 
C3     N/A    N/A    N/A    N/A    N/A 
D1      0      0       0        0       0  
 D2              1 (0.0)  5 (0.0)  2 (0.0)             42 (0.3)                 233(1.6) D3 
           25 (1.9)             23 (1.6)              31 (2.2)            0   12 (0.9) 
*)    The coding of error type is the same as the one used for the clinical database. 
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The most prevalent errors were: A2-incomplete EPID numbers, A3-discrepant year in EPID 
number and date of onset, C1-cases with negative interval between date of onset and the date 
stool sample was collected, D3 - isolates missing ITD results and C2 - cases with interval 
between onset of paralysis and date 2
nd
 stool was collected. Error code C2 had the highest 
incidence rate throughout the five year period ranging from 7.6% (2008) to 12.0% (2005). 
 
4.7. Distribution of Major Errors in the Laboratory Database 
The following results show the distribution of the errors identified in the laboratory database 
from 2004 to 2008.  
 
Table 9: Distribution of Cases with Incomplete EPID number (A2 error) by Laboratory, 
2004-2008 
Country    2004      2005  2006    2007  2008   
   n(%)       n(%)  n(%)    n(%)   n(%) 
Central African Republic  2 (4.9)    6 (16.2)   0      0     0 
Cote d’Ivoire       0        0    0  1 (0.4)     0      
Kenya    1(2.4)        0    0  2 (5.9)             4 (10.5)  
Nigeria (Maiduguri)     0        0    0     0             1 (2.6)      
Democratic Republic of Congo    0     2 (5.4) 2 (0.9)     0     0 
Senegal       0        0    0     0              1 (2.6) 
South Africa             36 (87.8)     24(64.9)     217 (93.9)     31(91.2)            30 (78.9)  
Uganda                1 (2.4)       1 (2.7) 4 (1.7)     0     0  
Zambia       0       2 (5.4)  0     0       0     
Zimbabwe               1 (2.4)       2 (5.4) 7 (3.0) 1 (2.9)             2 (5.3) 
Total     41       37  231     34  38        
 
Laboratories in Algeria, Cameroon, Ethiopia, Ghana, Nigeria, and Madagascar did not have A2 
type error for the five year period. The highest number of total cases with A2 error was recorded 
in 2006 (231) while the lowest number - in 2007 (34 cases). The laboratories that consistently 
had this error over a five year period were South Africa and Zimbabwe with former having 
highest proportion of them each year. Cote d’Ivoire had a single error in 2006 during the entire 
period under review.  
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Table 10: Distribution of cases with discrepant year in EPID number and date of onset of 
paralysis (A3 error code) by laboratory, 2004-2008 
Country    2004      2005  2006    2007  2008   
   n(%)       n(%)  n(%)     n(%)  n(%) 
Cameroon    0        0  2(4.9)        0              0 
Cote d’Ivoire     0        0  1(2.4)        0          1(8.3) 
Ethiopia      0        0          0      1(7.1)                0 
Ghana              1 (11.1)        0  7(17.1)     4(28.6)        2(16.7)   
Kenya              1 (11.1)        0  1(2.4)     3(21.4)              0          
Madagascar     0      1(16.7)     0               0                  0  
Nigeria (Maiduguri)    0       0  2(4.9)     1(7.1)           1 (8.3)      
Democratic Republic of Congo   0       0      2(4.9)         0             1 (8.3) 
Senegal      0       0  8(19.5)         0                 0 
South Africa             1 (11.1)     1(16.7)         10(24.4)     4(28.6)             0 
Uganda              1 (11.1)      1(16.7) 4(9.8)         0                 0   
Zambia              3 (33.3)      2(33.3) 4(9.8)         0                0         
Zimbabwe             2 (22.2)      1(16.7)    0     1(7.1)         2 (16.7) 
Total     9         6     41       14               7       
 
 
Laboratories from Algeria and Central African Republic did not have A3 error. The highest 
number of cases (41) with such discrepancies was recorded in 2006 while the least (6) was 
recorded in 2005. The laboratories that had errors for most of the years were South Africa, 
Ghana, and Zimbabwe. South Africa had highest proportion of discrepancies each year ranging 
from 11.1% in 2004 to 28.6% in 2007. Cameroon had the least number of errors (4.9%) in 2006. 
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Table 11: Distribution of cases with negative interval between date of onset and date stool 
specimen collection (C1 error code) by laboratory, 2004 – 2008. 
 
Country      2004      2005  2006    2007      2008  Total  
                n(%)       n(%)  n(%)    n(%)        n(%) 
Cameroun      1(5.9)       2(4.5)   0        0           0       2 
Cote d’Ivoire     1(5.9)           0     0        0           0       1 
Ghana          0       2(9.1)   0        0           0       2 
Nigeria (Ibadan)     2(11.8)             0           12(54.5)  7(31.8)           0     21 
Nigeria (Maiduguri)    3(17.6)      2(9.1)   0        0           0       5      
Kenya      1 (5.9)      2(9.1)  1(2.4)          0           0       4  
Democratic Republic of Congo   1(5.9)          0    0    4(23.5)          0       5 
Senegal      4(23.5)          0  1(4.5)    3(17.6)           0       8 
South Africa                0          0           12(54.5)        3(17.6)       1(25.0)     17     
Uganda      1(5.9)          0     0     1(5.9)            0       2 
Zambia      3(17.6)      2(9.1) 1(4.5)    5(29.4)      3(75.0)    17        
Zimbabwe          0     1(4.5)     0          1(5.9)            0      2 
Total          17         22                  22                17            4    86       
 
 
Laboratories from Algeria, Ethiopia, and Madagascar did not have C1 code error. Most of these 
errors were recorded in 2005 and 2006 with both years having 22 errors while in 2008 the 
number of errors dropped to 4. The highest number of errors over a five year period (21) was by 
one laboratory in Ibadan, Nigeria while Cote d’Ivoire had the least (1). The laboratory in Zambia 
had C1 code errors throughout the 5-year period.   
 
The following table represents errors in one of the important areas of polio surveillance: date of 
onset of AFP and date on which stool sample was collected which should be within 14 days 
following the onset of paralysis (C2 code). 
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Table 12: Distribution of cases where date of onset and date stool sample collected was 
greater than 14 days by laboratory, 2004-2008 (Error code C2) for all the laboratories in 
the listed countries 
 
Country    2004  2005  2006      2007  2008  
   n(%)        n(%)  n(%)       n(%)   n(%) 
Reported AFP cases  9761        11490  12299      12186              14254     
Algeria    8 (0.9)        16 (1.2)  13 (1.2)      28 (3.0)           35 (3.2) 
Cameroon      61(6.8)         55(4.0)  29(2.6)       53(5.7)            64(5.9) 
Central African Republic  18(2.0)          11(0.8)    6(0.5)        5 (0.5)             6 (0.6) 
Cote d’Ivoire   70(7.8)       124 (9.0) 30(2.7)      39 (4.2)           51 (4.7) 
Ethiopia    68(7.6)       167(12.1) 65(5.9)     98(10.5)        119(11.0) 
Ghana    24(2.7)        16 (1.2)                 15(1.4)       10(1.1)            29(2.7)  
Nigeria (Ibadan)   211(23.5)     282(20.4)          164(14.9)         79(8.5)       127(11.8)   
Nigeria (Maiduguri)  188(20.9)    315(22.8)          339(30.7)     120(12.9)       180(16.7) 
Kenya    51(5.7)          29(2.1)   58(5.3)         59(6.3)          50 (4.6)        
Madagascar   13 (1.4)         25(1.8)  15 (1.4)        10 (1.1)      180(16.7)  
Republic Democratic of Congo  47(5.2)      153(11.1)          176(16.0)      256(27.4)      195(18.1)  
Senegal     54(6.0)           66(4.8)          20(1.8)            8(3.0)           52(4.8)  
South Africa    30 (3.3)          46(3.3)           87(7.9)          69(7.4)          74(6.9)      
Uganda                22 (2.4)          42(3.0)    36(3.3)          54(5.8)         56(5.2)  
Zambia     17 (1.9)         15(1.1)    24(2.2)             9(1.0)  19(1.8)  
Zimbabwe    17(1.9)          19(1.4)   26(2.4)         16(1.7)          17(1.6)  
Total     899(9.2)     1381(12.0)    1103(9.0)       933(7.7)    1078(7.6)     
 
 
The highest number of reported cases with interval exceeding 14 days between date of onset and 
stool collection date was in 2005 (1381). Among the laboratories, the highest number of errors 
over a five year period was Maiduguri in Nigeria with 1142 errors while the laboratory in Central 
African Republic had only 46 errors.  
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4.8 Comparison of Extent of Different Errors in the Clinical and Laboratory databases 
Further analysis refers to discrepancies between clinical and laboratory databases illustrated in 
the series of graphs below. 
 
Figure 7 
Proportion of errors identified in clinical and laboratory databases, 2004-
2008
36%
64%
clinical database Laboratory database
 
 
 
Figure 7 indicates that the number of errors in the clinical database far exceeded those in the 
laboratory database representing 64% of the total.   
 
To find out what the differences in recorded error types between clinical and laboratory 
databases were the errors were analysed per major groups as shown in the following graphs.  
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Figure 8: Number of AFP cases with the discrepancy with EPID number wrong 
formulation (A1), incomplete (A2) and mismatch of dates (A3). 
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The graph illustrates comparatively higher number of errors (four-fold) in the clinical database 
against A1 error code. As for A2 code referring to incomplete EPID number and A3 (mismatch 
of year in EPID numbers) most of the errors in both cases were identified in the laboratory 
database.  
 
The next figure relates to error code block B on missing date of onset (B1) and mismatch of year 
in the databases (B2) showing that all errors were attributed to the clinical database with no 
errors recorded in the laboratory database.  
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Figure 9:  Errors in missing date of onset (B1) and mismatch of year of onset in the 
databases (B2). 
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There were 13 errors recorded against B1 error code and only 2 against B2 code.  
Figure 10 below refers to error code block “C” on collection of stool samples from AFP cases - 
one of the important aspects of polio surveillance. 
 
 
Figure 10:  Number of AFP cases with discrepancies in date of onset (C1), date stool sample 
collected (C2) and time between 2 stool samples (C3). 
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Analysis of the above figure shows comparatively low number of errors in C1 and C3 while C2 
constituted the major error in both databases with a slight domination in the clinical database.   
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As shown in figure 11 D1errors were identified only in the clinical database with high 
frequencies (3880 error cases). Some errors in D2 and D3 were shared between the clinical and 
laboratory databases with increased numbers in the former.    
 
Figure 11: Number of errors in block D code on cases missing dates specimen received in 
the laboratory (D1), missing primary isolation results (D2) and ITD results (D3)   
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4.9 Non-coded errors in databases 
This analysis included discrepancies between inter-related databases as well as the timeliness of 
specimen delivery from the field to central and laboratory levels. These errors were not included 
in the coded system categorized in table 4. 
 
4.9.1 Discrepancies in reported AFP cases and laboratory results between databases 
The table below illustrates differences in total numbers of reported AFP cases and positive 
isolates in both databases.  
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Table 13: Reported AFP cases in the clinical and laboratory databases over the period 2004 
to 2008 
  
Type of error  2004  2005  2006  2007  2008 
    n  n  n  n  n  
Clinical database 
Reported AFP cases 8560  11341  12067  11355  14296 
AFP with stools  8537  11312  12034  11333  14263 
Positive isolates  1270  1505  1562      721    1387 
 
Laboratory database 
AFP cases in       9761  11490  12152  12186  14254 
Positive isolates  1346    1405    1399     885    1300  
 
 
The table above clearly indicates significant inconsistencies both in numbers of reported AFP 
cases which are more in the laboratory database, and number of positive isolates. Throughout the 
five year period, with the exceptions of 2004 and 2007, the data indicated that the number of 
positive isolates in the clinical database was more than those in the laboratory.   
 
4.9.2 Timeliness of specimen movement from the field to the central level and from 
central level to the laboratory 
 
The third objective of the study focused on determining the timeliness of reporting, the 
proportion of cases in the clinical and laboratory databases received within 7 days at the central 
level and in the laboratory. The timeliness in the clinical database was calculated using date the 
stool sample was collected and the date it was received at central level while the laboratory 
timeliness was calculated using the date when the sample was sent to the laboratory and the date 
when it was received in the laboratory.   
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Findings in the study showed that while the number of reported AFP cases steadily improved in 
the clinical database from 8560 in 2004 to 14296 in 2008, the timeliness has constantly been 
50% or below compared to over 80% in the laboratory database (Table 12 and Figure 2). 
 
Table 14: Proportion of specimens from AFP cases received within 7 days at central level 
and by the laboratory 
Year       Clinical database             Laboratory database 
  Reported  AFP received   AFP cases     AFP received  
  AFP cases within 7 days   in Laboratory     within 7 days 
2004    8560  2346 (27.4%)      9761    8545 (88.5%) 
2005  11341  4662 (41.1%)   11490    9794 (85.2%) 
2006  12067  4561 (38.8%)   12299  10884 (88.5%) 
2007  11355  4344 (38.3%)   12186  10209 (84.8%) 
2008  14296  7156 (50.1%)   14254  12256 (86.0%) 
   
 
 
 
 
 
 
Table 15: Reported AFP cases in the clinical and laboratory databases 
  
Type of error  2004  2005  2006  2007  2008 
    n  n  n  n  n  
Clinical database 
Reported AFP cases 8560  11341  12067  11355  14296 
AFP with stools  8537  11312  12034  11333  14263 
Positive isolates  1270  1505  1562      721    1387 
 
Laboratory database 
AFP cases in       9761  11490  12152  12186  14254 
Positive samples  1346    1405    1399     885    1300  
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Figure 12: Percentage of timely stool specimens’ reception in laboratory (within seven days 
of shipment)  
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Figure 12 above shows that the numbers of specimen which were received in the laboratory and 
in time has almost remained unchanged, but well above the target of 80%, while timeliness of 
receipt of clinical data has increased significantly, almost two fold between 2004 and 2008, but 
without attaining the target of 80%.  The increase from 27 in 2004 to 41 in 2005 was statistically 
significant (P<0.005) 
Target 
 
 
 
 
 48 
CHAPTER FIVE 
 
DISCUSSIONS 
 
 
Clinical and Laboratory databases: Most of the study objectives were related to identification 
and quantification of errors in the clinical and laboratory databases maintained by the WHO, 
African Region. The current methods used for sharing data between the national AFP 
Surveillance programs and the inter-country laboratories may be plagued by poor data handling 
and transmission (de Gourville et al. 2006). Attempt to find a concise framework for 
identification of errors in the literature as a guidance to this study was not successful as there 
were few sources, especially related to errors in polio databases, in the African Region.  Unlike 
reported vaccination coverage data which can be validated through independent surveys (Murray 
et al. 2003) the quality of AFP data can only be assessed through reviews of records or datasets 
such as the present study.  
 
During this study an effort was made to develop an error framework with coding which included 
four major codes (A, B, C, D) and 11 sub codes, reflecting different elements of AFP 
surveillance. The error framework was informed by the knowledge of the variety of errors 
commonly encountered in AFP databases over the past years and also contributes significantly to 
the surveillance indicators. There is no doubt that this framework implying precise error 
categories if adapted throughout the African Region could facilitate a uniform approach in 
identifying data gaps and advising countries to rectify common errors thus improving overall 
AFP surveillance. In addition, the author also reviewed non-coded errors referring to 
inconsistencies of AFP cases reported and timeliness of stool specimens’ delivery from the field 
to central and laboratory levels.  
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The study reviewed a total of 57,619 clinical and 59,843 laboratory AFP cases reported during 
the period 2004 – 2008 by 46 member states of the WHO Regional Office for Africa. The study 
assessed the common errors in both databases and their implications on polio eradication 
programmes in the WHO African Region.  
Of the eleven types of errors identified, those errors relating to cases with pending laboratory 
results and cases with intervals between date of onset and stool collection or date specimen was 
received in the laboratory were found to be the most prevalent in both databases. The proportions 
of these two common types of errors were higher in the clinical database ranging from 7.7% in 
2004 to 58.9% in 2008 for cases missing intra-typic differentiation results compared to 
proportions in the laboratory database that had a range of 0.0% to 1.9% over the same period. 
Cases where the date of onset and date of stool collection was greater than 14 days was higher in 
both databases with slightly higher rates in the clinical database ranging from 8.6% in 2004 to 
13.3% in 2008 compared to 7.6%  and 12.0 in the laboratory database. These results confirm the 
earlier findings of inconsistency of immunization data at point of capture and after transfer of the 
data (Mavimbe, Braa and Bjune, 2005). Such errors as revealed by the present study call for 
action to be taken at the point of data capture or when data is transferred from one point to 
another, to minimize the introduction of errors.  
 
Critical indicators: Regarding the surveillance standard on annualized AFP rate (standard: 1 
AFP case per 100,000 children < 15 years of age), the present study has revealed that the African 
Region exceeds the target for this key indicator by several times, reporting 2.9 – 4.5 per 100,000 
children <15 years AFP cases throughout 2004-2008. Moreover, the Region also did well as for 
other important surveillance indicators requiring the collection of two stool specimens per an 
AFP case: 99% against the target of 80%. Based on these findings, the hypotheses 1 (section 1.6) 
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assuming that the AFP surveillance in the African Region show a sub-standard performance is 
rejected. 
 
Auditing AFP Surveillance Errors  
(a) Coded errors in clinical database: The analysis by major error groups in clinical database 
showed that in groups A (errors in EPID numbers) and especially group B (errors in date of 
onset) are not high (0.1-1.4%)  compared with the other two groups (C and D). In group C, the 
dominant error group was C2 (stool sample taken beyond 14 days of onset) contributing 13.3% 
of all errors in 2005, reduced to 8.6% in 2008 which should also be considered as high. The 
importance of this error is enormous as the likelihood of isolating virus in the stool is greatest if 
the specimens are collected within 14 days of onset of paralysis and that it diminishes markedly 
by 30 days (WHO, 2001).  This finding may explain why some WPV cases are not detected in 
time to initiate supplementary immunization until there has been a spread to other parts of the 
country or to other countries, resulting in the presence of orphan viruses and constituting a 
setback to the programme in the African region. 
 
The group D errors, having greater proportion among all errors categories, are indicative of poor 
interaction between those involved in compiling the clinical and laboratory databases. These 
errors refer to missing dates the laboratory received the samples (31.1%) as well as primary or 
ITD results submitted by laboratories to clinical databases (0.1-1.5%) and 2.4-34.,0%) 
respectively during the various years of the study. The sharp increase of D3 errors on ITD results 
in 2007 and 2008 may have been caused by changes in laboratory algorithm in 2007 reducing 
deadlines of submission of laboratory results from 28 to 14 days for primary isolation and after 
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primary results from 21 to 7 days for ITD results (AFRO memorandum to laboratories and 
countries, 2007).  
 
The analysis of the D1 error type by WHO sub-region and country indicates that countries in IST 
Central have the least number of errors with a significant reduction during 2004-2008 (from 308 
errors in 2004 to 19 in 2008) while the performance of the countries within the other two ISTs 
needs substantial overhaul due to high prevalence of D1 errors, not showing a meaningful 
decline during the study period. The most three D1 “error-infested” countries in IST West were 
Burkina Faso, Cote d’Ivoire, Guinea; in IST Central: Chad, Central African Republic, 
Democratic Republic of Congo and in the IST South/East: Namibia, Tanzania and South Africa. 
Based on the above discussion, the hypothesis 2 regarding inadequacy of AFP surveillance 
indicators in clinical database, is confirmed. One may speculate that the differences between 
countries and ISTs in terms of numbers of errors may be attributable to the differences in 
qualifications and the levels of experience of the staff in different countries as well as the 
workload. However since the present study did not specifically determine staff numbers per 
facility, qualifications and level of experience, it is impossible to assign specific reasons for the 
observed differences. Fundamentally errors in data can be attributed to the inability to accurately 
record, report, transmit and manage data (Bosch-Capblanch et al. 2009). At any point along the 
chain errors can be introduced, either through omissions, wrong entries, delays in transmission or 
combinations of these. Other studies have shown that the qualification of staff as well as the 
workload had very significant, direct influence on the quality of data collected at health facilities 
(Makombe et al. 20008). It is plausible that availability of staff, qualifications and workload may 
have contributed to the errors observed in the present study.   
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(b) Coded Errors in Laboratory databases:  In this database there are few errors related to 
wrong or incomplete formulation of EPID numbers and mismatch of dates (error code A) 
between EPID number and the date of onset. However, errors in C2 code were high amounting to 
7.7% - 12.0% during the study period. These errors are related to the key surveillance indicators 
such as the date of onset of paralysis and stool sample collected within 14 days of onset of 
paralysis. As discussed above, errors in this category can compromise the detection of the wild 
poliovirus in a sample. Relatively, more errors were recorded against error code D3 related to 
missed ITD results (0.9-2.2%) which may be related to the reluctance of staff to ensure the 
timely entry of results into the database or shortage of staff dealing with data. Indeed, in most 
laboratories, the technician who carries out the tedious laboratory analysis is also often 
responsible for entry of the results into the database. Engagement of data entry clerks with sole 
responsibility for this task could minimize the number of errors. Earlier studies (Harris et al. 
2003, Danovaro et al. 2007) referred to errors in data attributable to inadequate performance by 
demotivated personnel and high staff workload. Comparison of the frequency of the most 
prevalent errors by laboratories revealed that most errors related to code C2 were dominant, 
contributing up to 12.0% of all identified errors. Two laboratories located in Ibadan and 
Maiduguri in Nigeria, contributed approximately from 22% to 45% of errors among laboratories 
in the African Region. Based on this data, hypotheses 3, on lower rates of errors in the laboratory 
database as not being significant, is rejected.  By paying attention to these two laboratories and 
carrying out in-depth reviews the causes of the errors could be identified and quick remedial 
action taken to improve data quality and ensure polio eradication.    
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c) Non-coded errors in clinical and laboratory databases 
Inconsistencies of AFP records: Maintaining high data quality requires going through the data 
periodically, updating, standardizing and eliminating duplicates to create a single view of the 
data, even if it is stored in multiple disparate systems (WHO, 2001).  
 
The table 15 in results section clearly indicates significant inconsistencies both in numbers of 
reported AFP cases which are more in the laboratory database, and number of positive isolates. 
The data, throughout the five year period, with the exception of 2004 and 2007, indicated that the 
number of positive isolates in the clinical database was more than those in the laboratory 
database.   
 
The reason for mismatch of > 2300 AFP cases between the clinical and laboratory databases is 
not well understood although it could be attributed to some specimens being sent directly to the 
laboratory, thus bypassing the clinical database at national level. In a well-functioning 
surveillance system there should be cross-communication between two databases or those who 
manage them for harmonization of data. This aspect is not sufficiently addressed by existing 
reports to locate specific sources of this mismatch, and could be considered for further research 
at country level. It is also likely that the required periodic updating, standardizing and 
eliminating duplicates as recommended (WHO, 2001) is not being carried out. Elimination of 
such disparities is critical in ensuring that the goals of the GPEI are achieved and the region is 
certified free of poliomyelitis.   
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Timeliness: Timeliness of shipment of specimen from field to laboratory and between 
laboratories is a significant factor in determining the outcome of the final laboratory results. 
Findings in the present study showed that while the number of reported AFP cases steadily 
improved in the clinical database from 8560 in 2004 to 14296 in 2008, the timeliness constantly 
remained at 50% or below compared to over 80% for the laboratory database. This poor 
timeliness is an indication of possible problems in transportation of specimens from the field to 
the central level (WHO/Geneva, 2001). The implication of this delay in specimen transportation 
is that new WPV cases are not readily identified and in time to initiate the required 
supplementary immunization activities in line with the PEI strategy so as to eradicate the disease 
in Africa. 
 
 
d) Implications of identified errors on GPEI 
 
The present study identified the existence of errors against all of 11 error codes in both the 
clinical and laboratory databases, which is widespread in countries of the three ISTs of the WHO 
African region. In general, all these errors have implications for AFP surveillance and 
consequently the Global Polio Eradication Initiative, since they compromise  the accurate 
identification of infection with new WPV, information which is critical for the planning and 
implementation of vaccination campaigns in order to prevent the spread of the virus, ultimately 
the disease and attainment of certification of African Region as polio free as has been done in the 
South American and European Regions (de Quadros, 1997). 
 
Some of these implications are described in the table below related to each of the errors 
identified during the study, and their importance is indicated as per assessment scale.  
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While the present study assessed the quality of data and its implications to the polio eradication 
initiative in the African region, the study could not establish or assign accurate reasons for the 
errors which were identified since the study was retrospective. It was not possible to establish the 
timeline for correction of errors. Additional issues such as staff qualifications, experience and 
workload could not be ascertained and could be the subject of future studies. 
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CHAPTER SIX 
 
 
CONCLUSIONS AND RECOMMENDATIONS 
 
 
6.1 Conclusions 
The study reviewed a total of 57, 619 clinical and 59, 843 laboratory AFP cases reported during 
the period 2004 – 2008 by 46 Member States of the WHO Regional Office for Africa to find the 
extent of errors in both databases and their implications on polio eradication programmes in the 
WHO African Region. 
 
 
The study revealed that the African Region exceeds the target of 1 AFP/100,000 children <15 
years indicator required by the GPEI by several times reporting 2.9–4.5 per 100,000 children <15 
years AFP cases throughout 2004-2008. Moreover, the Region did also well as for other 
important surveillance indicators requiring the collection of two stool specimens per an AFP 
case: 99% against the target of 80%.  
 
The analysis by major error groups in clinical database showed that the proportion of records 
with errors in groups A and B are not high (0.1-1.4%) compared with other two groups (C and 
D). In group C, the dominant error group was C2 related to optimal time of specimen collection 
contributing 13.3% of all errors in 2005, reduced to 8.6% in 2008. 
 
 
 
 
 
 57 
The group D errors referring to missing date of specimen receipt in laboratory, having greater 
proportion among all errors categories, are indicative of poor interaction between clinical and 
laboratory databases or managers of these databases. 
 
The analysis of the D error type related to laboratory results by WHO sub-region and country 
indicates that countries in IST Central have least number of errors with a significant reduction 
from 308 to 19 errors while the performance of other two ISTs needs substantial overhaul due to 
high prevalence of D1 errors, not showing a meaningful decline during the study period. 
 
Comparison of the frequency of most prevalent errors by laboratories, revealed that most errors 
are related code C2 were dominate contributing up to 12.0% of all identified errors. Two 
laboratories located in Ibadan and Maiduguri in Nigeria, contributed approximately from 22% to 
45% of errors among laboratories in the African Region. Based on this data, hypotheses 3, on 
lower rates of errors in the laboratory database as being not significant, is rejected. 
 
Findings in the study showed that while the number of reported AFP cases steadily improved in the 
clinical database from 8560 in 2004 to 14296 in 2008, the timeliness of entering lab results has 
constantly been 50% or below compared to over 80% in the laboratory database. 
 
The study identified existence of errors against all of 11 error codes in both the clinical and laboratory 
databases. There are more errors in the clinical database than in the laboratory database. These errors 
have implications for the Global Polio Eradication Initiative with some of them being critical for 
certification of African Region as polio free. 
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6.2 Recommendations 
 
The following recommendations are proposed based on this study result: 
 Countries should improve on the capture of clinical data by engaging qualified staff, who 
should be well trained and motivated. 
 Countries are urged to improve mechanisms to clean and harmonize data between clinical 
and laboratory databases with a view to improving the quality of data. This is one of the 
conditions for attracting more support towards polio free certification status. 
 Targeted training through workshops or traveling seminars for staff working with data in 
both clinical and laboratory databases are recommended. 
 Organize cluster meetings or focus group discussions with data managers in countries 
with persistent problems or errors in their databases. 
 Organize exchange visits among data managers to share best practices in data handling.  
 Make presentations on the findings of this study during the annual EPI managers’ 
meetings in all three ISTs 
 What about the meeting of managers of the clinical and laboratory databases on frequent 
bases. 
 Where dedicated data entry staff are unavailable as is the case in most laboratories, well 
trained and motivated data entry staff should be engaged to enter laboratory data. 
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APPENDICES 
Appendix I: Case Investigation Form 
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Appendix II: Program used to generate EPID errors 
 
*****************************************************************************
************************ 
* PGM for selecting cases with Epid numbers wrongly formulated 
*****************************************************************************
************************ 
ROUTEOUT 'Epidnumber_Issues' REPLACE 
SORT Epidnumber 
DEFINE CTRY 
ASSIGN CTRY=SUBSTRING(EPIDNumber,1,3) 
 
SELECT substring( EpidNumber , 4 , 1 ) <> "-" or substring( EpidNumber , 8 , 
1 ) <> "-" or substring( EpidNumber , 12 , 1 ) <> "-" or substring( 
EpidNumber , 15 , 1 ) <> "-" 
IF RecordCount>0 THEN 
 TYPEOUT "Epidnumber Wrongly Formulated" (BOLD, UNDERLINE) TEXTFONT  4  
 FREQ CTRY 
 LIST EpidNumber NamesOfPAtient District DateOfOnset COLUMNSIZE=0 
END 
SELECT 
 
SELECT Substring(Epidnumber,14,1)="x" OR Substring(Epidnumber,16,1)="x" OR 
Substring(Epidnumber,14,1)="" OR Substring(Epidnumber,16,1)="" 
IF RecordCount>0 THEN 
 TYPEOUT "Epidnumber Incomplete" (BOLD, UNDERLINE) TEXTFONT  4  
 FREQ CTRY 
 LIST EpidNumber NamesOfPatient District DateOfOnset COLUMNSIZE=0 
END 
 
DEFINE YR_EPID 
DEFINE YR_ONSET 
ASSIGN YR_EPID=Substring(Epidnumber,13,2) 
ASSIGN YR_ONSET=Substring(FORMAT(YEAR(DateOfOnset)),3,2) 
SELECT NOT YR_EPID=YR_ONSET 
IF RecordCount>0 THEN 
 TYPEOUT "Epidnumber year and date of onset don’t match" (BOLD, 
UNDERLINE) TEXTFONT  4  
 FREQ CTRY 
 LIST EpidNumber NamesofPatient District DateOfOnset COLUMNSIZE=0 
END 
CLOSEOUT 
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Appendix III: Flow chart showing the collection, transfer and capture of both 
clinical and laboratory data, African Region 
 
 
 
 
 
Appendix IV:  Movement of specimens from field to laboratory by ISTs 
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Appendix V: Assessment of various errors and their implications for polio eradication 
programme   
 
 
Error 
type 
CODE 
Identified errors in the clinical and 
laboratory databases and their 
frequency in %% 
Importance of the error as 
per assessment scale 
Possible Implications on PEP 
High Medium Low  
A1 Wrong formulation of EPIDNumber    X  - When selecting a such a case using EPI Info 
coding such a case may be missed  
A2 Incomplete EPIDNumber  X   - Wrong location of case within or outside a 
country thereby initiating control measures 
where there is no virus 
A3 Year of EPID Number and date of 
ONSET do not match  
 
X 
 
 
 
 
- Difficult to determine which year of onset of 
case is correct. It may affect the polio free 
Certification Commission decision as a country 
should be certified polio free if the last 3 years 
zero cases are reported. 
 
B1 Cases missing date of onset X   - Difficult to determine which year the case 
happened thereby interfering with proper AFP 
rate 
- May also affect stool adequacy in view of stool 
being collected within 14 days 
B2 Cases with year of onset not 
matching with the year  
in the database 
 
 
 
 
X 
 
 
 
- Can increase or decrease the non-polio AFP 
rate for a particular year or location. 
C1 Date of onset and date 1st stool 
collected with negative interval  
 
X 
 
 
 
 
- Difficult to determine how timeliness of 
specimen collected from date of notification 
 
C2 Cases where date of onset and date 
2nd stool was collected  
is greater than 14 days  
 
X 
 
 
 
 
 
 
 
- Reduces the chances of virus isolation 
- indicates on poor polio surveillance in the area  
C3 Cases where the interval between  
date 1st stool was collected and date 
2nd stool was collected  
is negative or greater than 48hr 
 
 
X  - Affects chances for isolation of virus and in 
cases where 1st sample is inadequate or negative  
D1 Cases missing the date specimen 
received in the lab 
 
X 
 
 
 
 
- difficult to determine the time spent in 
transportation of specimens 
- affects timeliness of specimen shipment 
D2 Cases missing primary isolation 
results  
X   - Delays in decision making more especially 
when a case is suspected poliovirus 
- delays in expert committee to classify cases 
D3 Cases missing intra-typic 
differentiation  
results  
 
 
 
X 
 
 
- delays in decision making a mop up to 
undertake a mop up campaign especially when a 
case is confirmed polio virus 
- epidemiological linkages between AFP cases 
caused by same poliovirus type will be affected 
or impossible to establish 
 
Based on the above assessment of errors and their implications for the GPEI in the African 
Region, hypotheses number 4, is therefore confirmed. 
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Appendix VI: Current status of wild poliovirus outbreaks in the West and Horn of Africa (data as 
of April 2009). The red and blue dots and triangles depict countries with circulating WPV types 
1 and 3 respectively.   
 
 
Source: Polionews No.32, 1st Quarter, 2009 EDITION. WHO/CDC/UN IEF (2009) 
 
 
 
 
 
 
